NASDAQ : GRCE
Grace Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.94 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 40.81M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 8.22M | 8.67M | 7.17M | 6.68M | 8.28M | 6.58M |
| Research & Development | 2.15M | 2.40M | 9.51M | 4.59M | 9.93M | 5.56M |
| Operating Expenses | 10.37M | 11.08M | 16.68M | 11.28M | 18.21M | 12.14M |
| Operating Income | -10.37M | -11.08M | -16.68M | -11.28M | -18.21M | -12.14M |
| Interest & Investment Income | 621.00K | 685.00K | 711.00K | 911.00K | 246.00K | 77.00K |
| Currency Exchange Gain (Loss) | -25.00K | -1.00K | -17.00K | -16.00K | -72.00K | -299.00K |
| Other Non Operating Income (Expenses) | 1.39M | 900.00K | 3.22M | -2.73M | 10.00K | 5.34M |
| EBT Excluding Unusual Items | -8.39M | -9.49M | -12.77M | -13.11M | -18.02M | -7.02M |
| Merger & Restructuring Charges | -1.49M | -33.51M | -3.20M | |||
| Asset Writedown | -13.53M | -2.00K | -90.00K | -439.00K | -249.00K | |
| Pretax Income | -21.92M | -9.49M | -12.77M | -14.69M | -51.97M | -10.47M |
| Income Tax Expense | -1.70M | -1.70M | -3.20M | -1.83M | -9.54M | -648.00K |
| Net Income | -20.22M | -7.79M | -9.57M | -12.85M | -42.43M | -9.82M |
| Net Income to Common | -20.22M | -7.79M | -9.57M | -12.85M | -42.43M | -9.82M |
| Shares Outstanding (Basic) | 16.85M | 16.51M | 12.09M | 9.53M | 7.44M | 6.14M |
| Shares Outstanding (Diluted) | 16.85M | 16.51M | 12.09M | 9.53M | 7.44M | 6.14M |
| EPS (Basic) | -1.20 | -0.47 | -0.79 | -1.35 | -5.71 | -1.60 |
| EPS (Diluted) | -1.20 | -0.47 | -0.79 | -1.35 | -5.71 | -1.60 |
| Free Cash Flow | -10.29M | -8.87M | -14.90M | -12.36M | -15.93M | -17.23M |
| Free Cash Flow Per Share | -0.61 | -0.54 | -1.23 | -1.30 | -2.14 | -2.81 |
| EBITDA | -10.36M | -11.07M | -16.67M | -11.27M | -18.08M | -11.22M |
| D&A For EBITDA | 7.00K | 7.00K | 7.00K | 11.00K | 124.00K | 924.00K |
| EBIT | -10.37M | -11.08M | -16.68M | -11.28M | -18.21M | -12.14M |
Balance sheet
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 13.76M | 16.98M | 22.13M | 23.00M | 27.88M | 30.34M |
| Short-Term Investments | 15.00K | 13.32M | ||||
| Cash & Short-Term Investments | 13.76M | 16.98M | 22.13M | 23.00M | 27.89M | 43.66M |
| Other Receivables | 20.00K | 20.00K | 126.00K | 722.00K | 802.00K | 548.00K |
| Receivables | 20.00K | 20.00K | 126.00K | 722.00K | 802.00K | 548.00K |
| Prepaid Expenses | 557.00K | 383.00K | 453.00K | 283.00K | 598.00K | 720.00K |
| Other Current Assets | 352.00K | |||||
| Total Current Assets | 14.33M | 17.38M | 22.71M | 24.01M | 29.29M | 45.28M |
| Property, Plant & Equipment | 7.00K | 1.00K | 2.00K | 5.00K | 567.00K | 565.00K |
| Goodwill | 8.14M | 8.14M | 8.14M | 8.14M | 8.14M | 12.96M |
| Other Intangible Assets | 27.59M | 41.13M | 41.14M | 41.15M | 41.13M | 69.81M |
| Total Assets | 50.07M | 66.65M | 71.99M | 73.30M | 79.12M | 128.62M |
| Accounts Payable | 408.00K | 702.00K | 601.00K | 1.01M | 1.24M | 1.68M |
| Accrued Expenses | 842.00K | 1.44M | 1.33M | 677.00K | 2.09M | 1.48M |
| Current Portion of Leases | 75.00K | 104.00K | ||||
| Total Current Liabilities | 1.25M | 2.15M | 1.93M | 1.68M | 3.41M | 3.26M |
| Long-Term Leases | 410.00K | 191.00K | ||||
| Long-Term Deferred Tax Liabilities | 612.00K | 612.00K | 2.31M | 5.51M | 7.35M | 16.89M |
| Other Long-Term Liabilities | 1.14M | 4.36M | 10.00K | |||
| Total Liabilities | 1.86M | 2.76M | 5.38M | 11.56M | 11.17M | 20.35M |
| Common Stock | 1.00K | 1.00K | 1.00K | 1.00K | 258.29M | 257.99M |
| Additional Paid-In Capital | 298.52M | 298.41M | 293.33M | 278.90M | 13.96M | 12.15M |
| Retained Earnings | -244.27M | -228.48M | -220.69M | -211.12M | -198.27M | -155.84M |
| Comprehensive Income & Other | -6.04M | -6.04M | -6.04M | -6.04M | -6.04M | -6.04M |
| Shareholders' Equity | 48.21M | 63.90M | 66.61M | 61.74M | 67.95M | 108.27M |
| Total Liabilities & Equity | 50.07M | 66.65M | 71.99M | 73.30M | 79.12M | 128.62M |
| Total Debt | 485.00K | 295.00K | ||||
| Net Cash (Debt) | 13.76M | 16.98M | 22.13M | 23.00M | 27.41M | 43.37M |
| Net Cash Per Share | 0.82 | 1.03 | 1.83 | 2.41 | 3.69 | 7.06 |
| Filing Date Shares Outstanding | 21.04M | 16.27M | 13.83M | 9.40M | 7.44M | 7.38M |
| Total Common Shares Outstanding | 16.27M | 16.02M | 13.72M | 9.40M | 7.44M | 7.38M |
| Working Capital | 13.08M | 15.23M | 20.78M | 22.33M | 25.88M | 42.02M |
| Book Value Per Share | 2.96 | 3.99 | 4.86 | 6.57 | 9.14 | 14.67 |
| Tangible Book Value | 12.48M | 14.62M | 17.33M | 12.46M | 18.69M | 25.50M |
| Tangible Book Value Per Share | 0.77 | 0.91 | 1.26 | 1.33 | 2.51 | 3.45 |
| Machinery | 3.00K | 5.00K | 613.00K | 674.00K | 696.00K |
Cash flow statement
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Net Income | -20.22M | -7.79M | -9.57M | -12.85M | -42.43M | -9.82M |
| Depreciation & Amortization | 7.00K | 7.00K | 7.00K | 11.00K | 124.00K | |
| Loss (Gain) From Sale of Assets | 2.00K | -20.00K | 400.00K | |||
| Asset Writedown & Restructuring Costs | 13.53M | 33.55M | 249.00K | |||
| Stock-Based Compensation | 601.00K | 798.00K | 730.00K | 913.00K | 1.81M | 1.34M |
| Other Operating Activities | -3.09M | -2.60M | -6.42M | 896.00K | -9.55M | -6.21M |
| Change in Accounts Receivable | 106.00K | 596.00K | 80.00K | -302.00K | -18.00K | |
| Change in Accounts Payable | -1.06M | 543.00K | -84.00K | -1.65M | 411.00K | -2.39M |
| Change in Other Net Operating Assets | -57.00K | 70.00K | -170.00K | 292.00K | 72.00K | -380.00K |
| Operating Cash Flow | -10.29M | -8.87M | -14.90M | -12.33M | -15.91M | -17.23M |
| Capital Expenditures | -22.00K | -17.00K | ||||
| Sale of Property, Plant & Equipment | 111.00K | |||||
| Investment in Securities | 15.00K | 13.17M | -3.52M | |||
| Investing Cash Flow | 104.00K | 13.15M | -3.52M | |||
| Issuance of Common Stock | 4.04M | 4.04M | 15.00M | 7.52M | 304.00K | |
| Other Financing Activities | -327.00K | -967.00K | -162.00K | |||
| Financing Cash Flow | 4.04M | 3.71M | 14.03M | 7.36M | 304.00K | |
| Foreign Exchange Rate Adjustments | -8.00K | 153.00K | ||||
| Net Cash Flow | -6.25M | -5.16M | -872.00K | -4.87M | -2.46M | -20.60M |
| Free Cash Flow | -10.29M | -8.87M | -14.90M | -12.36M | -15.93M | -17.23M |
| Free Cash Flow Per Share | -0.61 | -0.54 | -1.23 | -1.30 | -2.14 | -2.81 |
| Levered Free Cash Flow | -7.00M | -5.73M | -9.01M | -7.40M | -9.06M | -4.57M |
| Unlevered Free Cash Flow | -7.00M | -5.73M | -9.01M | -7.40M | -9.06M | -4.57M |
| Change in Working Capital | -1.12M | 719.00K | 342.00K | -1.28M | 181.00K | -2.79M |
Ratios
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 39.76M | 71.64M | 31.28M | 32.19M | 20.52M | 54.03M |
| Enterprise Value | 26.00M | 52.97M | 20.22M | 7.10M | -10.24M | 7.73M |
| Last Close Price | 1.94 | 4.63 | 2.28 | 3.42 | 2.76 | 7.32 |
| PB Ratio | 0.65 | 1.12 | 0.47 | 0.52 | 0.30 | 0.50 |
| P/TBV Ratio | 3.27 | 4.90 | 1.80 | 2.58 | 1.10 | 2.12 |
| Debt / Equity Ratio | 0.01 | 0.00 | ||||
| Net Debt / Equity Ratio | -0.28 | -0.27 | -0.33 | -0.37 | -0.40 | -0.40 |
| Net Debt / EBITDA Ratio | 1.33 | 1.53 | 1.33 | 2.04 | 1.51 | 3.87 |
| Net Debt / FCF Ratio | 1.34 | 1.91 | 1.49 | 1.86 | 1.72 | 2.52 |
| Quick Ratio | 11.02 | 7.92 | 11.53 | 14.09 | 8.41 | 13.56 |
| Current Ratio | 11.47 | 8.10 | 11.77 | 14.26 | 8.59 | 13.89 |
| Return on Equity (ROE) | -36.19% | -11.94% | -14.91% | -19.82% | -48.15% | -11.98% |
| Return on Assets (ROA) | -10.81% | -9.99% | -14.35% | -9.25% | -10.96% | -7.94% |
| Return on Capital Employed (ROCE) | -21.20% | -17.20% | -23.80% | -15.70% | -24.00% | -9.70% |
| Earnings Yield | -63.51% | -10.88% | -30.59% | -39.92% | -206.80% | -18.17% |
| FCF Yield | -25.21% | -12.38% | -47.65% | -38.38% | -77.64% | -31.90% |
| Buyback Yield / Dilution | -26.32% | -36.59% | -26.85% | -28.16% | -21.09% | -148.46% |